CERN-Led PRISMAP Program Fuels Breakthroughs in Cancer Research with Novel Radionuclides
Table of Contents
A European initiative coordinated by CERN has delivered a significant boost to cancer research, supplying 159 batches of crucial radioactive materials to laboratories across 19 countries over the past five years. The program, known as PRISMAP, is designed to overcome a key hurdle in the development of new cancer treatments: access to specialized radionuclides.
The Rise of Theranostics and the Need for Radionuclides
Nuclear medicine utilizes radionuclides – unstable nuclei that emit radiation – for both imaging and therapeutic purposes. This radiation can be harnessed to damage or destroy cancer cells. Over the last decade, a revolutionary approach called “theranostics” has gained prominence, combining diagnostic imaging with targeted therapy to personalize cancer treatment for each patient. While two radiopharmaceuticals have already been authorized for use in treating neuroendocrine and prostate cancers, the development pipeline remains robust, yet hampered by limited access to the necessary radioactive isotopes during early-stage research.
PRISMAP: Bridging the Gap in Radionuclide Access
The primary goal of PRISMAP – the European medical radionuclides programme – was to address this critical need by providing access to new, high-purity radionuclides, thereby accelerating research into targeted medical treatments. “By connecting eight radionuclide production facilities and five biomedical research centres across Europe, the project has undoubtedly stimulated research into cancer treatment,” explained a senior official associated with the program.
Over the five-year period, PRISMAP directly supported 47 medical research projects. Beyond simply supplying the materials, the program also offered researchers the opportunity to conduct projects at its five biomedical facilities, providing access to specialized equipment and necessary authorizations.
Alpha Emitters and the Future of Cancer Treatment
A particularly promising avenue of research supported by PRISMAP focuses on alpha-emitting radionuclides. These particles, composed of two protons and two neutrons, offer a unique advantage in cancer therapy. They target cancer cells with greater precision than other forms of radiation, minimizing damage to healthy tissue and proving particularly effective against micro-metastases – a major challenge in oncology.
CERN-MEDICIS, a unique facility dedicated to producing radionuclides by mass separation for biomedical research, plays a central role in this effort. This process results in exceptionally pure isotopes. By combining radionuclides produced in traditional cyclotrons and nuclear reactors with CERN-MEDICIS’s mass separation techniques, the program has delivered innovative materials to researchers.
Lead Isotopes and Prostate Cancer Research
One notable example of PRISMAP’s impact involves the combination of two isotopes of lead. Pb-203, sourced from the ARRONAX cyclotron in Nantes, France, was combined with Pb-212 from CERN-MEDICIS and delivered to Dresden Hospital for research into diagnostics and treatment for prostate cancer. “The PRISMAP project was instrumental in developing this highly innovative theranostic approach,” a program coordinator stated. “The initial results recently published are very encouraging.”
Looking Ahead: PRISMAP+ and Continued Innovation
The original PRISMAP project concluded on December 31, 2025. Recognizing the program’s success, a funding request has been submitted for a three-year follow-up project, PRISMAP+, aimed at continuing and expanding the network. This continued investment underscores the vital role of PRISMAP in advancing cancer research and bringing innovative treatments closer to reality.
